KTRA (Kintara Pharma) Company Cash on Hand

Kintara Therapeutics adheres to basic environmental standards by disposing of laboratory waste. The cash-on-hand metric helps track the financial stability of this sector, where 0.00 represents the latest level. Kintara Therapeutics develops drugs to combat aggressive brain tumors through DNA modification. Business efficiency is maintained through strict temperature control during the delivery of experimental medications to medical centers.
Financial and market metric breakdowns for Kintara Therapeutics, Inc. (KTRA)

This indicator measures the issuer's liquid reserves, determining the time horizon before a cash shortfall occurs, accounting for reporting lags. For Kintara Therapeutics (KTRA), this metric is critical due to high R&D expenditures in oncology. By analyzing the volume of cash holdings, one can assess the company's ability to fund the development of anti-tumor drugs. An increase in balances may indicate a capital inflow or the sale of assets. It is essential for investors to compare this reserve with the cash burn rate.